Kenneth Poels
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kenneth Poels has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Dirk Verellen
Department of Radiation Oncology, Iridium Network, Wilrijk (Antwerp), Belgium; Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium
11 shared publications - Thierry Gevaert
Department of Radiotherapy, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium
8 shared publications - Benedikt Engels
Department of Radiotherapy, UZ Brussel, Vrije Universiteit Brussel, Belgium
6 shared publications - Christine Collen
Department of Radiotherapy, UZ Brussel, Vrije Universiteit Brussel, Belgium
6 shared publications Mark De Ridder
Department of Radiotherapy, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Belgium
6 shared publicationsTom Depuydt
Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium
6 shared publications
Latest Publications
- 31 October 2023
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 68 (21) , 21NT02
Extended in-field and out-of-field validation of a compact Monte Carlo model of an IBA PROTEUS®ONE proton beam in TOPAS/GEANT4
Objective: This study evaluates a compact Monte Carlo (MC) model of a pencil beam scanning clinical proton beam using TOPAS to estimate the dose out-of-field (OOF). Compact modelling means that the model starts from a pristine proton beam at the nozzle exit, customised based on acceptance and commissioning data, instead of modelling the full treatment head and room. Approach: First, in-field validation tests were performed. Then, the OOF dose was validated in an RW3 phantom with bubble detectors for personal neutron dosimetry (measuring the neutron dose equivalent) and thermoluminiescent detectors (measuring the absorbed dose by protons and gammas). Measurements were performed at 15 and 35 cm from the distal edge of the field for five different irradiation plans, covering different beam orientations, proton energies and a 40 mm range shifter. TOPAS simulations were performed with QGSP Binary Cascade HP (BIC) and QGSP Bertini HP (Bertini) hadron physics lists. Main results: In-field validation shows that MC simulations agree with point dose measurements within −2.5 % and +1.5 % at locations on- and off-axis and before, in and after the Bragg peak or plateau. The gamma passing rate 2%/3mm of four simulated treatment plans compared to the dose distribution calculated by the TPS exceeds 97 % agreement score. OOF dose simulations showed an average overestimation of 27 % of the neutron dose equivalent for the BIC hadron physics list and an average underestimation of 20 % for the Bertini hadron physics list. The simulated absorbed dose of protons and gammas showed a systematic underestimation which was on average 21 % and 51 % for BIC and Bertini respectively. Significance: Our study demonstrates that a compact MC model can reliably produce in-field data, while out-of-field dose data are within the uncertainties of the detector systems and MC simulations nuclear models, and do so with shorter modelling and faster calculation time.
- 31 October 2023
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 68 (21) , 21NT02
Extended in-field and out-of-field validation of a compact Monte Carlo model of an IBA PROTEUS®ONE proton beam in TOPAS/GEANT4
Objective: This study evaluates a compact Monte Carlo (MC) model of a pencil beam scanning clinical proton beam using TOPAS to estimate the dose out-of-field (OOF). Compact modelling means that the model starts from a pristine proton beam at the nozzle exit, customised based on acceptance and commissioning data, instead of modelling the full treatment head and room. Approach: First, in-field validation tests were performed. Then, the OOF dose was validated in an RW3 phantom with bubble detectors for personal neutron dosimetry (measuring the neutron dose equivalent) and thermoluminiescent detectors (measuring the absorbed dose by protons and gammas). Measurements were performed at 15 and 35 cm from the distal edge of the field for five different irradiation plans, covering different beam orientations, proton energies and a 40 mm range shifter. TOPAS simulations were performed with QGSP Binary Cascade HP (BIC) and QGSP Bertini HP (Bertini) hadron physics lists. Main results: In-field validation shows that MC simulations agree with point dose measurements within −2.5 % and +1.5 % at locations on- and off-axis and before, in and after the Bragg peak or plateau. The gamma passing rate 2%/3mm of four simulated treatment plans compared to the dose distribution calculated by the TPS exceeds 97 % agreement score. OOF dose simulations showed an average overestimation of 27 % of the neutron dose equivalent for the BIC hadron physics list and an average underestimation of 20 % for the Bertini hadron physics list. The simulated absorbed dose of protons and gammas showed a systematic underestimation which was on average 21 % and 51 % for BIC and Bertini respectively. Significance: Our study demonstrates that a compact MC model can reliably produce in-field data, while out-of-field dose data are within the uncertainties of the detector systems and MC simulations nuclear models, and do so with shorter modelling and faster calculation time.
- 1 April 2021
- Published by Elsevier in European Urology Oncology
- Vol. 4 (2) , 305-309
Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer
- 1 April 2021
- Published by Elsevier in European Urology Oncology
- Vol. 4 (2) , 305-309
Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer
- Open Access
- 29 April 2016
- Published by Springer Nature in Radiation Oncology
- Vol. 11 (1) , 63
Initial characterization, dosimetric benchmark and performance validation of Dynamic Wave Arc
Dynamic Wave Arc (DWA) is a clinical approach designed to maximize the versatility of Vero SBRT system by synchronizing the gantry-ring noncoplanar movement with D-MLC optimization. The purpose of this study was to verify the delivery accuracy of DWA approach and to evaluate the potential dosimetric benefits. DWA is an extended form of VMAT with a continuous varying ring position. The main difference in the optimization modules of VMAT and DWA is during the angular spacing, where the DWA algorithm does not consider the gantry spacing, but only the Euclidian norm of the ring and gantry angle. A preclinical version of RayStation v4.6 (RaySearch Laboratories, Sweden) was used to create patient specific wave arc trajectories for 31 patients with various anatomical tumor regions (prostate, oligometatstatic cases, centrally-located non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer-LAPC). DWA was benchmarked against the current clinical approaches and coplanar VMAT. Each plan was evaluated with regards to dose distribution, modulation complexity (MCS), monitor units and treatment time efficiency. The delivery accuracy was evaluated using a 2D diode array that takes in consideration the multi-dimensionality of DWA during dose reconstruction. In centrally-located NSCLC cases, DWA improved the low dose spillage with 20 %, while the target coverage was increased with 17 % compared to 3D CRT. The structures that significantly benefited from using DWA were proximal bronchus and esophagus, with the maximal dose being reduced by 17 % and 24 %, respectively. For prostate and LAPC, neither technique seemed clearly superior to the other; however, DWA reduced with more than 65 % of the delivery time over IMRT. A steeper dose gradient outside the target was observed for all treatment sites (p < 0.01) with DWA. Except the oligometastatic cases, where the DWA-MCSs indicate a higher modulation, both DWA and VMAT modalities provide plans of similar complexity. The average ɣ (3 % /3 mm) passing rate for DWA plans was 99.2 ± 1 % (range from 96.8 to 100 %). DWA proven to be a fully functional treatment technique, allowing additional flexibility in dose shaping, while preserving dosimetrically robust delivery and treatment times comparable with coplanar VMAT.
- 29 April 2016
- Published by Springer Nature in Radiation Oncology
- Vol. 11 (1) , 63
Open AccessInitial characterization, dosimetric benchmark and performance validation of Dynamic Wave Arc
Dynamic Wave Arc (DWA) is a clinical approach designed to maximize the versatility of Vero SBRT system by synchronizing the gantry-ring noncoplanar movement with D-MLC optimization. The purpose of this study was to verify the delivery accuracy of DWA approach and to evaluate the potential dosimetric benefits. DWA is an extended form of VMAT with a continuous varying ring position. The main difference in the optimization modules of VMAT and DWA is during the angular spacing, where the DWA algorithm does not consider the gantry spacing, but only the Euclidian norm of the ring and gantry angle. A preclinical version of RayStation v4.6 (RaySearch Laboratories, Sweden) was used to create patient specific wave arc trajectories for 31 patients with various anatomical tumor regions (prostate, oligometatstatic cases, centrally-located non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer-LAPC). DWA was benchmarked against the current clinical approaches and coplanar VMAT. Each plan was evaluated with regards to dose distribution, modulation complexity (MCS), monitor units and treatment time efficiency. The delivery accuracy was evaluated using a 2D diode array that takes in consideration the multi-dimensionality of DWA during dose reconstruction. In centrally-located NSCLC cases, DWA improved the low dose spillage with 20 %, while the target coverage was increased with 17 % compared to 3D CRT. The structures that significantly benefited from using DWA were proximal bronchus and esophagus, with the maximal dose being reduced by 17 % and 24 %, respectively. For prostate and LAPC, neither technique seemed clearly superior to the other; however, DWA reduced with more than 65 % of the delivery time over IMRT. A steeper dose gradient outside the target was observed for all treatment sites (p < 0.01) with DWA. Except the oligometastatic cases, where the DWA-MCSs indicate a higher modulation, both DWA and VMAT modalities provide plans of similar complexity. The average ɣ (3 % /3 mm) passing rate for DWA plans was 99.2 ± 1 % (range from 96.8 to 100 %). DWA proven to be a fully functional treatment technique, allowing additional flexibility in dose shaping, while preserving dosimetrically robust delivery and treatment times comparable with coplanar VMAT.
- 1 July 2015
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 92 (4) , 754-761
Geometric Verification of Dynamic Wave Arc Delivery With the Vero System Using Orthogonal X-ray Fluoroscopic Imaging
- 1 July 2015
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 92 (4) , 754-761
Geometric Verification of Dynamic Wave Arc Delivery With the Vero System Using Orthogonal X-ray Fluoroscopic Imaging
- 1 June 2015
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 115 (3) , 412-418
A multi-centre analysis of treatment procedures and error components in dynamic tumour tracking radiotherapy
- 1 June 2015
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 115 (3) , 412-418
A multi-centre analysis of treatment procedures and error components in dynamic tumour tracking radiotherapy
- 29 October 2014
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 113 (3) , 371-373
Analysis of the targeting uncertainty of a stereotactic frameless radiosurgery technique for arteriovenous malformation
- 29 October 2014
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 113 (3) , 371-373
Analysis of the targeting uncertainty of a stereotactic frameless radiosurgery technique for arteriovenous malformation
- 1 October 2014
- Published by Wiley in Medical Physics
- Vol. 41 (10) , 101911
Fiducial marker and marker‐less soft‐tissue detection using fast MV fluoroscopy on a new generation EPID: Investigating the influence of pulsing artifacts and artifact suppression techniques
Purpose:: Because frame rates on current clinical available electronic portal imaging devices (EPID's) are limited to 7.5 Hz, a new commercially available PerkinElmer EPID (XRD 1642 AP19) with a maximum frame rate of 30 Hz and a new scintillator (Kyokko PI200) with improved sensitivity (light output) for megavolt (MV) irradiation was evaluated. In this work, the influence of MV pulse artifacts and pulsing artifact suppression techniques on fiducial marker and marker‐less detection of a lung lesion was investigated, because target localization is an important component of uncertainty in geometrical verification of real‐time tumor tracking.Methods:: Visicoil™ markers with a diameter of 0.05 and 0.075 cm were used for MV marker tracking with a frame rate of, respectively, 7.5, 15, and 30 Hz. A 30 Hz readout of the detector was obtained by a 2 × 2 pixel binning, reducing spatial resolution. Static marker detection was conducted in function of increasing phantom thickness. Additionally, marker‐less tracking was conducted and compared with the ground‐truth fiducial marker motion. Performance of MV target detection was investigated by comparing the least‐square sine wave fit of the detected marker positions with the predefined sine wave motion. For fiducial marker detection, a Laplacian‐of‐Gaussian enhancement was applied after which normalized cross correlation was used to find the most probable marker position. Marker‐less detection was performed by using the scale and orientation adaptive mean shift tracking algorithm. For each MV fluoroscopy, a free running (FR‐nF) (ignoring MV pulsing during readout) acquisition mode was compared with two acquisition modes intending to reduce MV pulsing artifacts, i.e., combined wavelet‐FFT filtering (FR‐wF) and electronic readout synchronized with respect to MV pulses.Results:: A 0.05 cm Visicoil marker resulted in an unacceptable root‐mean square error (RMSE) > 0.2 cm with a maximum frame rate of 30 Hz during FR‐nF readout. With a 30 Hz synchronized readout (S‐nF) and during 15 Hz readout (independent of readout mode), RMSE was submillimeter for a static 0.05 cm Visicoil. A dynamic 0.05 cm Visicoil was not detectable on the XRD 1642 AP19, despite a fast synchronized readout. For a 0.075 cm Visicoil, deviations of sine wave motion were submillimeter (RMSE < 0.08 cm), independent of the acquisition mode (FR, S). For marker‐less tumor detection, FR‐nF images resulted in RMSE > 0.3 cm, while for MV fluoroscopy in S‐mode RMSE < 0.1 cm for 15 Hz and RMSE < 0.16 cm for 30 Hz. Largest consistency in target localization was experienced during 15 Hz S‐nF readout.Conclusions:: In general, marker contrast decreased in function of higher frame rates, which was detrimental for marker detection success. In this work, Visicoils with a thickness of 0.075 cm were showing best results for a 15 Hz frame rate, while non‐MV compatible 0.05 cm Visicoil markers were not visible on the new EPID with improved sensitivity compared to EPID models based on a Kodak Lanex Fast scintillator. No noticeable influence of pulsing artifacts on the detection of a 0.075 cm Visicoil was observed, while a synchronized readout provided most reliable detection of a marker‐less soft‐tissue structure.
- 1 October 2014
- Published by Wiley in Medical Physics
- Vol. 41 (10) , 101911
Fiducial marker and marker‐less soft‐tissue detection using fast MV fluoroscopy on a new generation EPID: Investigating the influence of pulsing artifacts and artifact suppression techniques
Purpose:: Because frame rates on current clinical available electronic portal imaging devices (EPID's) are limited to 7.5 Hz, a new commercially available PerkinElmer EPID (XRD 1642 AP19) with a maximum frame rate of 30 Hz and a new scintillator (Kyokko PI200) with improved sensitivity (light output) for megavolt (MV) irradiation was evaluated. In this work, the influence of MV pulse artifacts and pulsing artifact suppression techniques on fiducial marker and marker‐less detection of a lung lesion was investigated, because target localization is an important component of uncertainty in geometrical verification of real‐time tumor tracking.Methods:: Visicoil™ markers with a diameter of 0.05 and 0.075 cm were used for MV marker tracking with a frame rate of, respectively, 7.5, 15, and 30 Hz. A 30 Hz readout of the detector was obtained by a 2 × 2 pixel binning, reducing spatial resolution. Static marker detection was conducted in function of increasing phantom thickness. Additionally, marker‐less tracking was conducted and compared with the ground‐truth fiducial marker motion. Performance of MV target detection was investigated by comparing the least‐square sine wave fit of the detected marker positions with the predefined sine wave motion. For fiducial marker detection, a Laplacian‐of‐Gaussian enhancement was applied after which normalized cross correlation was used to find the most probable marker position. Marker‐less detection was performed by using the scale and orientation adaptive mean shift tracking algorithm. For each MV fluoroscopy, a free running (FR‐nF) (ignoring MV pulsing during readout) acquisition mode was compared with two acquisition modes intending to reduce MV pulsing artifacts, i.e., combined wavelet‐FFT filtering (FR‐wF) and electronic readout synchronized with respect to MV pulses.Results:: A 0.05 cm Visicoil marker resulted in an unacceptable root‐mean square error (RMSE) > 0.2 cm with a maximum frame rate of 30 Hz during FR‐nF readout. With a 30 Hz synchronized readout (S‐nF) and during 15 Hz readout (independent of readout mode), RMSE was submillimeter for a static 0.05 cm Visicoil. A dynamic 0.05 cm Visicoil was not detectable on the XRD 1642 AP19, despite a fast synchronized readout. For a 0.075 cm Visicoil, deviations of sine wave motion were submillimeter (RMSE < 0.08 cm), independent of the acquisition mode (FR, S). For marker‐less tumor detection, FR‐nF images resulted in RMSE > 0.3 cm, while for MV fluoroscopy in S‐mode RMSE < 0.1 cm for 15 Hz and RMSE < 0.16 cm for 30 Hz. Largest consistency in target localization was experienced during 15 Hz S‐nF readout.Conclusions:: In general, marker contrast decreased in function of higher frame rates, which was detrimental for marker detection success. In this work, Visicoils with a thickness of 0.075 cm were showing best results for a 15 Hz frame rate, while non‐MV compatible 0.05 cm Visicoil markers were not visible on the new EPID with improved sensitivity compared to EPID models based on a Kodak Lanex Fast scintillator. No noticeable influence of pulsing artifacts on the detection of a 0.075 cm Visicoil was observed, while a synchronized readout provided most reliable detection of a marker‐less soft‐tissue structure.
- 1 September 2014
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 112 (3) , 352-359
Improving the intra-fraction update efficiency of a correlation model used for internal motion estimation during real-time tumor tracking for SBRT patients: Fast update or no update?
- 1 September 2014
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 112 (3) , 352-359
Improving the intra-fraction update efficiency of a correlation model used for internal motion estimation during real-time tumor tracking for SBRT patients: Fast update or no update?